These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27975242)

  • 21. Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains.
    Nagamine S; Yamazaki T; Makioka K; Fujita Y; Ikeda M; Takatama M; Okamoto K; Yokoo H; Ikeda Y
    Neuropathology; 2016 Aug; 36(4):333-45. PubMed ID: 26685795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dependence of the Formation of Tau and Aβ Peptide Mixed Aggregates on the Secondary Structure of the N-Terminal Region of Aβ.
    Rojas AV; Maisuradze GG; Scheraga HA
    J Phys Chem B; 2018 Jul; 122(28):7049-7056. PubMed ID: 29940109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.
    Guillozet-Bongaarts AL; Garcia-Sierra F; Reynolds MR; Horowitz PM; Fu Y; Wang T; Cahill ME; Bigio EH; Berry RW; Binder LI
    Neurobiol Aging; 2005 Jul; 26(7):1015-22. PubMed ID: 15748781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of human tau 3D structure, and interplay between O-β-GlcNAc and phosphorylation modifications in Alzheimer's disease: C. elegans as a suitable model to study these interactions in vivo.
    Ahmad W; Shabbiri K; Ahmad I
    Biochem Biophys Res Commun; 2020 Jul; 528(3):466-472. PubMed ID: 32499112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential Binding and Conformational Dynamics of Tau Microtubule-Binding Repeats with a Preformed Amyloid-β Fibril Seed.
    Song Z; Gatch AJ; Sun Y; Ding F
    ACS Chem Neurosci; 2023 Apr; 14(7):1321-1330. PubMed ID: 36975100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impacts of Cd(II) on the conformation and self-aggregation of Alzheimer's tau fragment corresponding to the third repeat of microtubule-binding domain.
    Jiang LF; Yao TM; Zhu ZL; Wang C; Ji LN
    Biochim Biophys Acta; 2007 Nov; 1774(11):1414-21. PubMed ID: 17920001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
    Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
    Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ubiquitin is associated with early truncation of tau protein at aspartic acid(421) during the maturation of neurofibrillary tangles in Alzheimer's disease.
    García-Sierra F; Jarero-Basulto JJ; Kristofikova Z; Majer E; Binder LI; Ripova D
    Brain Pathol; 2012 Mar; 22(2):240-50. PubMed ID: 21919991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective effects of Wnt/β-catenin signaling pathway against Aβ -induced tau protein over-phosphorylation in PC12 cells.
    Wang J; Jing Y; Song L; Xing Y
    Biochem Biophys Res Commun; 2016 Mar; 471(4):628-32. PubMed ID: 26809093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interplay of isoform 1N4R tau protein and amyloid-β peptide fragment 25-35 in reducing and non-reducing conditions.
    Mohammadi F; Takalloo Z; Rahmani H; Nasiri Khalili MA; Khajeh K; Riazi G; H Sajedi R
    J Biochem; 2021 Feb; 169(1):119-134. PubMed ID: 32857841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution.
    Friedhoff P; Schneider A; Mandelkow EM; Mandelkow E
    Biochemistry; 1998 Jul; 37(28):10223-30. PubMed ID: 9665729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Longest Amyloid-β Precursor Protein Intracellular Domain Produced with Aβ42 Forms β-Sheet-Containing Monomers That Self-Assemble and Are Proteolyzed by Insulin-Degrading Enzyme.
    Krasinski CA; Zheng Q; Ivancic VA; Spratt DE; Lazo ND
    ACS Chem Neurosci; 2018 Dec; 9(12):2892-2897. PubMed ID: 30067897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS.
    Ma Q; Li Y; Du J; Liu H; Kanazawa K; Nemoto T; Nakanishi H; Zhao Y
    Peptides; 2006 Apr; 27(4):841-9. PubMed ID: 16225961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation.
    Santa-María I; Hernández F; Moreno FJ; Avila J
    Neurosci Lett; 2007 Dec; 429(2-3):91-4. PubMed ID: 17976912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.
    Thal DR; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324
    [No Abstract]   [Full Text] [Related]  

  • 38. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease.
    Salminen A; Ojala J; Kaarniranta K; Hiltunen M; Soininen H
    Prog Neurobiol; 2011 Jan; 93(1):99-110. PubMed ID: 21056617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains.
    Zhou XW; Li X; Bjorkdahl C; Sjogren MJ; Alafuzoff I; Soininen H; Grundke-Iqbal I; Iqbal K; Winblad B; Pei JJ
    Neurobiol Dis; 2006 Jun; 22(3):657-68. PubMed ID: 16513361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.